NCT06707493View on ClinicalTrials.gov

Ivosidenib as Post-HSCT Maintenance for AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 8, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2030

Conditions
IDH1 MutationAcute Myeloid Leukemia (AML)Hematopoietic Stem Cell Transplant (HSCT)
Interventions
DRUG

Ivosidenib

Ivosidenib tablets are supplied as 50 mg, 200 mg, and 250 mg strengths, to be taken orally.

DRUG

Placebo

Placebo tablets are taken orally.

Trial Locations (2)

02114

RECRUITING

Massachusetts General Hospital, Boston

02115

NOT_YET_RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

Massachusetts General Hospital

OTHER